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Abstract 
 
Background: Although sinus node dysfunction is primarily related to degenerative fibrosis of 
nodal tissue in the elderly, it may occur at any age secondary to other cardiac abnormalities 
or extrinsic causes. Pharmacologic agents including psychotropic drug therapy may also play 
a role.  
Method: We present the case of a 53-year-old woman with bipolar affective disorder in 
whom antipsychotic agents were suspected of inducing sinus node dysfunction.  
Result: The combination of psychotropic agents including lithium, quetiapine, and 
carbamazepine (first occasion) or escitalopram (second occasion) has been implicated as a 
cause for sinus node dysfunction.  
Conclusion: Patients with severe mental illness usually require long-term psychotropic drug 
therapy, often in combination. This may enhance efficacy but also involves an increased risk 
of adverse effects including cardiotoxicity. 
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Introduction 
 
Sinus node dysfunction is a frequent cardiac disorder in the elderly that may occur due to 
intrinsic causes (abnormality of impulse generation/formation or propagation because of age-
related fibrosis, coronary artery disease, etc.) or extrinsic causes (pharmacologic agents, 
electrolyte imbalances, autonomic nervous system dysfunction, hypothyroidism, 
hypothermia, etc.). ECG manifestations include sinus bradycardia, sinus arrest, sinoatrial 
block, atrial fibrillation with slow ventricular response, and bradycardia-tachycardia 
syndrome. More than one manifestation can occur in the same patient on different occasions 
(1). In the present case, antipsychotic agents were suspected of inducing sinus node 
dysfunction.  
 
Case report 
 
A 53-year-old woman was referred to the cardiology department with severe fatigue and a 
slow heart rate. Her past medical history included lumbar spondylosis, hyperlipidemia, 
bipolar affective disorder, post-thyroidectomy (20 yrs previously) and L-thyroxin substitution 
therapy. Her medications included lithium carbonate (250 mg b.i.d.), carbamazepine (200 mg 
q.d.), quetiapine (200 mg q.d.), atorvastatin (40 mg), levothyroxin (150 µg), clonazepam (1-
1-2 mg), cinolazepam (40 mg). Previous electrocardiogram (ECG) records showed normal 
sinus rhythm seven and six months before the admission. 
Her physical examination was remarkable for obesity (BMI 31.9), tremor and bradycardia 
with a heart rate of 45 beats per minute. A complete blood count, repeated serum troponin T, 
serum electrolyte levels measurements, and tests of kidney, liver, and thyroid function were 
all normal. An ECG on admission showed sinus bradycardia and junctional escape rhythm. 
Mobitz II type second degree sinoatrial block was later observed (Fig.1,2). She was admitted 
to a coronary care unit to permit continuous ECG monitoring. One hour later temporary 
pacing was applied using an external transvenous pacemaker due to the evolving 
symptomatic 7-second-long sinus arrest (Fig.3).  
A transthoracic echocardiogram demonstrated left ventricle hypertrophy, normal left ventricle 
size and systolic function with an estimated ejection fraction of 69%, mild left atrial 
enlargement (42 mm) and mild aortic valve regurgitation, without significant wall motion 
abnormalities. 
Because the patient attempted suicide two years earlier, giving up lithium was inadvisable. 
Lithium’s antisuicidal effect is independent from its mood-stabilising property; and lithium 
evidently lowers suicide mortality even in moderate and poor responders (2). Whereas 
suicide-prevention effects have not been shown for long-term anticonvulsant treatment (3). 
Consequently, carbamazepine administration was discontinued. Normal sinus rhythm 
gradually returned in two days, with a heart rate of 70 beats per minute. The temporary 
pacemaker was switched off on the third day. Continuous ECG monitoring showed stable 
sinus rhythm during the following days until the patient was discharged. ECG showed 
negative T waves in leads I, II, V2-5, but the exercise stress test results and thallium scans did 
not reveal significant coronary artery disease. Therefore, these repolarization abnormalities 
could be in connection with a transient change in the direction of cardiac activation due to 
ventricular pacing that might persist for a while after the end of pacing (cardiac memory 
phenomenon). The patient was discharged in a good general condition after nine days, she did 
not consent to coronary angiography. A cardiology control examination found normal sinus 
rhythm three months later. 
Five months after the first episode, she was readmitted to the cardiology department because 
of palpitation and fatigue from the day before. Ten days prior to admission, 200 mg 
ketoconazole once per day had been initiated for intertrigo under the breasts. At that time her 
medications included lithium carbonate (500 mg b.i.d.), escitalopram (10 mg), quetiapine 
(200 mg q.d.), amiloride (5 mg), hydrochlorothiazide (50 mg), acetylsalicylic acid (100 mg), 
levothyroxin (150 µg), clonazepam (0.5-0.5-3 mg), cinolazepam (40 mg) and ketoconazole 
(200 mg). Her physical examination and laboratory test findings were within normal limits.  
In the coronary care unit, continuous ECG monitoring was carried out that revealed 
intermittent sinus bradycardia with a heart rate of 45 bpm. Occasional episodes of sinus arrest 
(with a maximum of 2.6 s) also occurred with junctional escape beats followed by short 
episodes of atrial fibrillation or atrial tachycardia (Fig.4).  
Ketoconazole was discontinued. The patient’s mental status did not allow giving up her 
antipsychotic or antidepressant therapy. Temporary pacing was not necessary at this time, 
sinus rhythm with a heart rate of 60 bpm returned in one day and remained stable. Four days 
later, she was discharged in a good condition. Because cessation of the antipsychotic and 
antidepressant therapy was not possible, one month later a permanent VVI pacemaker was 
implanted to prevent subsequent bradyarrhythmia episodes. 
 
Discussion 
 
This patient presented two episodes of symptomatic sinus node dysfunction with different 
ECG manifestations (sinus bradycardia, Mobitz II second degree sinoatrial block, sinus 
arrest, tachycardia-bradycardia syndrome). Though not fully ruled out, intrinsic causes were 
unlikely because of the relative young age, negative history for angina pectoris and normal 
results with noninvasive tests (echocardiography, exercise stress test, and thallium scan) that 
did not demonstrate coronary artery disease. Thyroid stimulating hormone was in the normal 
range with substitution, excluding hypothyroidism as a cause. The patient was not on 
medication with well-known sinus node function affecting action (digitalis, beta-blockers, 
non-dihidropyridine calcium channel blockers, antiarrhythmic drugs) but her medications 
included psychotropic agents that might explain the bradycardia.  
Lithium carbonate is frequently used for the treatment of manic-depressive disorders, without 
significant cardiotoxicity in most patients. However, chronic lithium therapy has been 
associated with a wide range of cardiac side effects, including asymptomatic 
electrocardiographic changes, sinoatrial, and atrioventricular conduction disturbances, 
tachyarrhythmias, myocarditis and congenital heart disease (4). Reversible T-wave flattening 
and subclinical or symptomatic sinus node dysfunction are the most frequently reported 
cardiac abnormalities. Conduction abnormalities may occur even at subtherapeutic serum 
lithium levels (5).  
Carbamazepine, a drug used primarily for the treatment of epilepsy, neuralgias and bipolar 
disorder, was also reported to exert cardiac side effects. Sinus node dysfunction, 
atrioventricular block, and bradycardia-tachycardia syndrome have been observed during 
carbamazepine treatment when used alone or when coadministered with lithium (6-8). The 
mechanism is unclear, though, in animal models, carbamazepine was shown to block cardiac 
Na+ channels in a frequency-independent manner (9). Most case reports describe 
bradyarrhythmias in elderly women even at therapeutic carbamazepine serum levels (10).  
Quetiapine, an atypical antipsychotic agent, is usually well tolerated and possesses minimal 
proarrhythmic effects (11). However, QTc prolongation and first-degree atrioventricular 
block were reported with quetiapine overdose (12, 13). Moreover, sinus bradycardia has been 
observed in two quetiapine-treated patients without QT interval prolongation (14, 15). 
Quetiapine is extensively metabolized by the cytochrome P450 system, primarily by CYP3A 
(16). Concomitant administration with ketoconazole, a potent CYP3A4 inhibitor, may lead to 
a significant reduction in the first-pass metabolism and hepatic clearance of quetiapine and 
thus potentially increase adverse effects. Coadministration of ketoconazole increased mean 
Cmax of quetiapine by 3.35-fold and decreased its clearance by 84% in vivo (17).  
Ketoconazole is also an inhibitor of P-glycoprotein (Pgp) and may increase plasma 
concentrations of Pgp substrates (18). Quetiapine has been suggested to be a substrate for this 
transporter (19). On the contrary, Grimm et al. demonstrated that quetiapine is not a substrate 
of Pgp (17). Therefore, the interaction is likely to take place only on the metabolic level.  
On the other hand, coadministration of carbamazepine, a potent CYP3A4 inductor, leads to a 
decrease in serum levels and clinical efficacy of quetiapine (17). In the present case, 
discontinuation of carbamazepine after the first episode might also have increased quetiapine 
serum levels.  
Selective serotonin reuptake inhibitors (SSRIs) are the first line therapy for depression and 
anxiety due to their tolerability. In contrast to tricyclic antidepressants, long-term SSRI 
therapy is not associated with an elevated risk of cardiovascular disease (20). However, 
among other SSRIs, citalopram, and its more effective S-enantiomer, escitalopram, can exert 
cardiotoxic effects, probably due to inhibition of cardiac Na+, Ca2+ and K+ channels (21, 22). 
Citalopram induced bradycardia has been reported in overdose or at therapeutic doses in the 
elderly (23). Beyenburg et al. presented a case of severe bradycardia caused by a single small 
dose (5 mg) of escitalopram (24). Escitalopram is metabolised by CYP2C19, CYP2D6 and 
CYP3A4 (25). Though theoretically concomitant therapy with CYP3A4 inhibitor 
ketoconazole might have resulted in an increased plasma concentration of escitalopram, that 
is not likely due to the several metabolic pathways of the antidepressant agent.  
Patients with severe mental illness often require long-term treatment with a combination of 
psychotropic drugs. However, as far as possible, polypharmacy should be avoided to prevent 
dangerous interactions. If concomitant use of potentially cardiotoxic agents is necessary, 
clinicians should routinely monitor the ECG at least at baseline and after initiation of a new 
drug. Moreover, if the cardiotoxic drug is a CYP substrate, dose titration is also advisable 
after initiation of a potent CYP inhibitor.  
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